IPF Catalyst Challenge recognizes Owlstone Medical’s Breath Biopsy platform

[News]

Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, today announced it is one of the three winners of the global Idiopathic Pulmonary Fibrosis (IPF) Catalyst Challenge, sharing the $1,000.000 (£720,000 GBP) award, each receiving $333,333 (£240,000 GBP).

More... (https://www.news-medical.net/news/20180127/IPF-Catalyst-Challenge-recognizes-Owlstone-Medicale28099s-Breath-Biopsy-platform.aspx)